Connectivity and function of a mature nervous system requires precise wiring between neurons and with target cells throughout embryonic development. Severe to mild errors in connectivity lead to neurodevelopmental disorders ranging from profound intellectual deficits to subtle behavioral abnormalities ([@bib16]). For example, evidence from many groups has shown defective neuronal connections in several autism spectrum disorders, such as Fragile X syndrome and tuberous sclerosis complex, as well as in motor deficits and degenerative muscle diseases ([@bib13]; [@bib6]; [@bib3]). However, most disease etiologies cannot be unilaterally attributed to abnormal axon guidance, as many of the relevant proteins are functional in other important neurological processes, such as dendritic spine maturation and function ([@bib10]; [@bib11]).

One key player involved in morphogenesis and innervation of developing neurons is the nerve growth cone, the dynamic and motile sensory tip of growing axons and dendrites. Growth cones function with a large degree of autonomy from the cell soma, as they transduce contacted soluble and substratum-bound ligands into signals that coordinate cytoskeletal changes to regulate the rate and direction of axon outgrowth ([@bib12]). Both growth-promoting and -inhibiting molecules are expressed along the pathways of developing axons and local discontinuities (e.g., gradients and borders) of extracellular cues are amplified into local biochemical changes within growth cones. Although many groups have given us insight into these processes over the past few decades, crucial mechanisms underlying guidance are still poorly understood ([@bib9]). In this issue, Wang et al. demonstrate that Down syndrome critical region 1 protein (DSCR1) has two distinct roles in growth cones to control neurite outgrowth and guidance.

Importantly, biochemical changes within growth cones have been shown to both directly modulate the cytoskeleton and indirectly affect motility by regulating local synthesis of new proteins ([@bib11]). Despite significant advances, it is still unclear why and how growth cones use protein synthesis--independent and --dependent mechanisms to regulate motility. Precise spatiotemporal control of translation likely provides additional levels of cellular regulation. For example, local protein synthesis is controlled by numerous mRNA binding and trafficking proteins, which may be regulated by classic second messengers ([@bib1]). Many proteins synthesized at the growth cone are ubiquitinated at a higher rate than those trafficked from the cell body, and protein degradation is regulated by axon guidance cues ([@bib5]). Distinct pathways could also be activated by newly synthesized proteins via their relative lack of posttranslational modifications. Finally, new protein synthesis may sensitize growth cones to different types and concentrations of ligands. Interestingly, in vitro experiments have shown that basal axon outgrowth is independent of local protein synthesis, whereas local protein synthesis is necessary for guidance. For example, [@bib13] found that in a mouse model of tuberous sclerosis complex, which displays a defect in the regulation of the mTOR complex (a translational hub in the growth cone), Ephrin A--dependent local protein synthesis was required for proper retinogeniculate mapping, but no defects in retinal axon growth were observed ([@bib13]). It is also interesting to note that several inherited autism spectrum disorders exhibit misregulation of protein synthesis ([@bib16]), suggesting these mechanisms have important roles in human central nervous system assembly.

Down syndrome, or trisomy 21, affects human development and is caused, in part, by elevated expression of genes encoded by chromosome 21, resulting in intellectual disabilities. One particular protein implicated is DSCR1 ([@bib7]), also known as regulator of calcineurin (RCAN1). One established function of DSCR1 is to inhibit calcineurin (CaN), which is a calcium- and calmodulin-dependent serine/threonine protein phosphatase. DSCR1 binds and inhibits CaN, whereas phosphorylation of DSCR1 releases CaN, which may actively or passively lead to CaN activation. DSCR1 and CaN are highly expressed in developing neurons ([@bib7]), where they may cooperate to control morphological differentiation. DSCR1 also interacts with Fragile X mental retardation protein (FMRP), which is lost in Fragile X syndrome ([@bib17]; [@bib18]). FMRP is an mRNA binding protein that regulates local protein synthesis in dendritic spines and neuronal growth cones ([@bib2]; [@bib15]). Moreover, previous results from [@bib4] suggest that DSCR1 and FMRP1 may participate in common biological pathways leading to intellectual disability, including the maturation of dendritic spines.

In their most recent work, [@bib19] demonstrate that DSCR1 serves a dual function in growth cones to regulate both neurite outgrowth and guidance. Gain and loss of function of DSCR1 leads to increased and decreased axon extension in developing mouse hippocampal neurons, respectively. Consistent with the role of DSCR1 as a CaN inhibitor, DSCR1^−/−^ growth cones have elevated CaN activity as indicated by reduced phosphorylated cofilin (nonphosphorylated cofilin is the active form of this actin depolymerizing factor), which leads to loss of F-actin and short axons. In contrast, DSCR1 transgenic neurons, which express 1.5-fold excess DSCR1 compared with wild-type neurons, display elevated phosphorylated cofilin (the inactive form) and increased F-actin in their growth cones, increasing neurite extension.

In chemotropic turning assays, DSCR1^−/−^ neurons fail to orient toward brain-derived neurotrophic factor (BDNF), whereas transgenic DSCR1 neurons exhibit enhanced turning. Interestingly, [@bib19] find that although activation of CaN and cofilin caused by loss of DSCR1 function reduces axon extension, misregulation of CaN is not responsible for defective chemotropic turning toward BDNF by DSCR1^−/−^ neurons. This result suggests that a different DSCR1-dependent target regulates axon turning. Here, [@bib19] find that local protein synthesis in response to BDNF depends on DSCR1 and Fmr1. They show that enhanced protein synthesis in growth cones and axon turning in DSCR1 transgenic neurons is abrogated in Fmr1 knockdown neurons. Together these results support a model where DSCR1 functions as an important regulatory switch to direct distinct aspects of axon growth and guidance machinery.

[@bib19] illustrate for the first time divergent activities of DSCR1 in the regulation of axon outgrowth and guidance, but many open questions remain. For example, there appears to be an important difference between the regulation of DSCR1 in axon guidance versus dendritic spine morphogenesis. Previous work by [@bib18] showed that Fmr1 is dephosphorylated by CaN in response to BDNF, which promotes protein translation. However, in their current work, inhibition of CaN does not prevent chemotropic turning toward a BDNF, which depends on DSCR1, Fmr1 and protein synthesis. Therefore, the role of CaN-mediated dephosphorylation of Fmr1 downstream of BDNF and DSCR1 is unclear in growth cone turning. It is also interesting to note that [@bib19] observe changes in total cofilin levels in growth cones from DSCR1 transgenic and knockout neurons, as well as after inhibition of CaN, suggesting that there may be homeostatic aspects of regulation of these pathways yet to be explored. Given the complexities of cofilin regulation in actin polymerization and evidence that cofilin can be locally translated in axons ([@bib14]), it is clear that additional work is necessary to understand these pathways more completely.

Finally, how DSCR1 dysfunction contributes specifically to neural developmental disorders associated with Down syndrome is not known. DSCR1 gain-of-function experiments may most closely match chromosomal triplication conditions in developing trisomy 21 neurons. Under these conditions, [@bib19] find increased axon extension, as well as enhanced turning toward BDNF by mouse hippocampal neurons. However, it is not clear how elevated DSCR1 expression will affect CaN-cofilin signaling and protein synthesis downstream of the wide range of growth promoting and inhibiting guidance cues that use these signals ([@bib8]). It is also not clear how DSCR1 overexpression will affect human neurons under similar conditions. To address this question, specific classes of excitatory and inhibitory neurons differentiated from human embryonic stem cells and induced pluripotent stem cells (hiPSCs) should be tested. For example, in these in vitro systems, Crispr-Cas--mediated correction of specific genes of hiPSCs from Down syndrome patients or selected triplication of chromosome 21 target genes of unaffected hiPSCs could be used to test the necessity and sufficiency of specific genes on cellular phenotypes observed in vitro. If specific requirements for DSCR1 or other candidate genes can be identified by assaying neuronal morphogenesis of human cells in vitro, these findings would provide an excellent platform for therapeutic drug screening of treatments that rescue these cellular phenotypes.
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